Analytical Characterization of Label-Free Immunosensor Subsystems Based on Multi-Walled Carbon Nanotube Array-Modified Gold Interface

Zahmatkeshan, Masoumeh; Ilkhani, Hoda; Paknejad, Mojgan; Adel, Moein; Sarkar, Saeed; Saber, Reza

doi:10.2174/1386207318666141212165513

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanotechnology has played an important role in diagnosing and treating cancer, including TNBC [13][14][15]. Researchers have extensively studied nanotechnology to enhance the efficacy of chemotherapeutic agents by promoting their bioavailability and reducing toxicity of off-target cells [16].…”

Section: Introductionmentioning

confidence: 99%

Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line

Sabzandam,

Zahmatkeshan,

Adel

et al. 2023

Zaštita materijala

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for 15-20% of all invasive breast cancers and has a poor prognosis. ZnO NPs are promising anti-cancer agents. Moreover, folate Alpha receptor (FRa) is a potential biomarker and therapeutic target because it is significantly expressed in TNBC. Therefore, ZnO and folic acid-conjugated ZnO (F-ZnO) NPs were synthesized by the solgel method. NPs were characterized by DLS, zeta potential, TEM, FTIR, and ICP-MS. FA-ZnO NPs had a mean diameter of 20 ± 2 nm and a surface charge of -15 mV, while ZnO NPs had a mean diameter of 40 ± 5 nm and a surface charge of -5 mV. The MTT assay and trypan blue test, respectively, were used to determine the cytotoxicity and viability percentage of ZnO and F-ZnO NPs at different concentrations of 2, 4, 8, 16, 32, 64 and 128 µg/mL for 12, 24, 48 and 72 hours (h) on the human TNBC cell line MDA-MB-231. The results indicated that both ZnO and F-ZnO NPs significantly reduced the viability of the cancer cells in a dose-dependent and time-dependent manner (p<0.05). The IC50 values for FA-ZnO NPs were approximately 3, 3.74, 4.38 and 5.5 times higher than those for ZnO NPs at 12-, 24-, 48and 72-hour time points, respectively. The results suggest that F-ZnO NPs have the potential to be a good option for TNBC treatment and warrant further investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line

Sabzandam,

Zahmatkeshan,

Adel

et al. 2023

Zaštita materijala

Self Cite

View full text Add to dashboard Cite

show abstract

“…To overcome these drawbacks, various research fields have been focused on novel diagnosis, prevention, and treatment methods [9] , [10] , [11] . As a result, a range of natural and synthetic materials have been proposed and developed for therapeutic applications.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles

Adel

Zahmatkeshan

Akbarzadeh

et al. 2022

Biotechnology Reports

Self Cite

View full text Add to dashboard Cite

“…The most common types of immunosensors are found in electrochemical [7,[14][15][16][17][18][19][20][21], optical [22,23], and gravimetric [24] sensors. It is well known that electrochemical detection methods have been able to sensitively and quickly detect biomolecule targets with high selectivity [25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Design of an Affibody-Based Recognition Strategy for Human Epidermal Growth Factor Receptor 2 (HER2) Detection by Electrochemical Biosensors

2016

Self Cite

View full text Add to dashboard Cite

Abstract:In this study, we have designed and realized three simple electrochemical bioassays for the detection of the human epidermal growth factor receptor 2 (HER2) cancer biomarker using magnetic beads coupling screen-printed arrays. The different approaches were based on a sandwich format in which affibody (Af) or antibody (Ab) molecules were coupled respectively to streptavidin or protein A-modified magnetic beads. The bioreceptor-modified beads were used to capture the HER2 protein from the sample and sandwich assay was performed by adding the labeled secondary affibody or the antibody. An enzyme-amplified detection scheme based on the coupling of secondary biotinylated bioreceptor with streptavidin-alkaline phosphatase enzyme conjugate was then applied. The enzyme catalyzed the hydrolysis of the electro-inactive 1-naphthyl-phosphate to the electro-active 1-naphthol, which was detected by means of differential pulse voltammetry (DPV). Each developed assay has been studied and optimized. Furthermore, a thorough comparison of the analytical performances of developed assays was performed. Finally, preliminary experiments using serum samples spiked with HER2 protein were also carried out.

show abstract

Analytical Characterization of Label-Free Immunosensor Subsystems Based on Multi-Walled Carbon Nanotube Array-Modified Gold Interface

Cited by 9 publications

References 0 publications

Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line

Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line

Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles

Design of an Affibody-Based Recognition Strategy for Human Epidermal Growth Factor Receptor 2 (HER2) Detection by Electrochemical Biosensors

Contact Info

Product

Resources

About